Cancer Chemotherapy and Selective Drug Development: Proceedings of the 10th Anniversary Meeting of the Coordinating Committee for Human Tumour Investigations, Brighton, England, October 24–28, 1983
K.R. Harrap, W. Davis, A.H. Calvert
Springer, Aug 31, 1984 - Medical - 585 pages
Over the past 30 years many significant advances have been made in the management of a number of disseminated malignant diseases. The prognosis for diseases such as childhood leukaemia, choriocarcinoma and Hodgkin's disease has gradually been transformed as better anti tumour agents have become available and their clinical use has been refined. During the past 10 years the advent of new agents, particularly cisplatin, bleomycin and the podophyllotoxins, has allowed the cure of disseminated testicular tumours. This degree of success has not, however, been achieved in the case of a number of other common cancers. Ovarian carcinoma is tantalisingly chemo-sensitive and although there are long term survivors from disseminated disease, these are only a small proportion of the total. Breast cancer, although "sensitive" to a multitude of drugs appears to have yielded neither survival benefit, nor cure to the efforts of therapists, while tumours such as those of the colon remain stubbornly unresponsive. Against this backcloth it is apparent that additional more selective treatments are needed if further impact is to be made on the problem of cancer. The development of such agents requires the integration of a multidisciplinary effort encompassing the fields of chemistry, biology and medicine. This symposium provided a forum for clinical and preclinical sCientists, where current aspects of cancer treatment were reviewed and approaches to the development of a new generation of more selective anticancer drugs discussed.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Clinical drug resistance
New therapies with old drugs
Antimetabolite combinations possessing enhanced efficacy
63 other sections not shown
Other editions - View all
Cancer Chemotherapy and Selective Drug Development: Proceedings of the 10th ...
K.R. Harrap,W. Davis,A.H. Calvert
No preview available - 2011
acid adjuvant adriamycin advanced breast cancer alkylating agents aminoglutethimide analgesic analogue antibody anticancer antiemetic antiestrogens antigen antitumour activity assay BCNU binding Biochem biological bone marrow breast cancer Cancer Res Cancer Research Cancer Treat carcinoma cell lines chemotherapy chlorambucil chromatin cisplatin clinical trials combination chemotherapy compound concentrations crosslinking cyclophosphamide cytosol cytotoxic differentiation disease drug DTIC effect endocrine enzyme estradiol estramustine evaluation experimental fluorouracil growth high dose histone hormone Hospital human tumour IMP dehydrogenase increase incubation induced inhibition inhibitors interferon interstrand leukaemia levels lymphocytes lymphokines lymphoma malignant mammary matrix melanoma melphalan metabolism metastases methotrexate mice misonidazole mitoxantrone monoclonal murine nitrosoureas normal nuclear nuclei Oncology ovarian pain patients pharmacokinetics Pharmacol phase plasma platinum polyamines potential Proc proteins remission renal resistance response rate sensitive serum shown studies survival synthesis Table tamoxifen therapeutic therapy thymidine tissue toxicity transplantation treatment tumour tumour cells vitro vivo xenografts